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1250 The Journal of Thoracic and CardObjective: We sought to study the clinical characteristics and outcomes of patients
treated with a surgery-inclusive multimodality approach for Pancoast tumors.
Methods: Clinical records of patients with Pancoast lung cancer who were enrolled
for multimodality treatment between 1993 and 2003 at our institution were reviewed
retrospectively.
Results: Thirty-six patients completed neodjuvant chemoradiation followed by en
bloc surgical resection, whereas one patient received high-dose radiation alone
followed by surgical intervention. There were 22 men and 15 women. Thirty-four
lobectomies and 3 pneumonectomies were performed. Pretreatment non–small cell
lung cancer stages were IIB, IIIA, IIIB, and IV (presenting with solitary brain
metastasis) in 18, 8, 6, and 5 cases, respectively. R0 resection was achieved in 36
(97.3%) patients. Operative mortality was 2.7% (n  1). High-dose radiotherapy
was successfully tolerated in all but 1 patient. Mean total radiation dose was 56.9
Gy. Pathologic complete response was found in 40.5% (n  15) of patients.
Recurrences were found in 50% (n  18) of patients. Brain metastasis was the most
common recurrence (n 9), followed by other distant recurrences (n 4) and local
recurrences (n  5). Median survival time for the group is 2.6 years, and median
survival time (pathologic complete response) is 7.8 years. It is noteworthy that
median survival time of patients with positive pretreatment lymph nodes (12
patients) was not reached.
Conclusions: Surgical resection of Pancoast tumors after neoadjuvant high-dose
radiation and chemotherapy can be safely performed. High-dose radiation in trimo-
dality treatment is well tolerated and might be beneficial. Similar to other studies,
late central nervous system relapse is problematic and indicates a need for assessing
the role of prophylactic cranial irradiation in this disease.
The eponym Pancoast tumor derives from the noted Philadelphia radiologistDr. Henry K. Pancoast’s description of these superior sulcus tumors in hisclassic article published in 1924.1 Currently accepted criteria characterizing
Pancoast tumors emphasize features such as location at the superior sulcus and
involvement of structures of the apical chest wall above the level of the second rib.2
Symptomatology in patients with Pancoast tumors might be quite variable, depend-
ing on which apical structures are affected by local tumor abutment or invasion.
Although Pancoast tumors comprise less than 5% of all lung cancers, the significant
morbidity of untreated tumors and the challenges inherent in effectively treating
these cancers because of their anatomic location have provided tremendous incen-
tive to clinicians to seek improved outcomes in this select patient population.
In the last 40 years, the treatment of Pancoast tumors has centered on a
bimodality regimen consisting of preoperative external beam radiotherapy followed
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TSby surgical resection, as serendipitously discovered and
subsequently described in 1961 by Shaw and Paulson.3,4
The recent addition of chemotherapy to preoperative radia-
tion is motivated by the rationale of improving resectability
rates and preventing systemic disease.5-8 However, the op-
timum neoadjuvant radiation dosage or chemotherapy reg-
imen remains to be determined. In this article we examined
our center’s experience with Pancoast tumors in the last
decade to assess the effects of high-dose radiation instituted
in a neoadjuvant setting with combination chemotherapy on
clinical outcomes.
Methods
We retrospectively analyzed all patients with Pancoast tumors
treated with a multimodality approach at our institution from 1993
through 2003. Tumors involving the chest wall only and deemed
resectable by means of surgical intervention alone were not in-
cluded in this study. This study was approved by the Institutional
Review Board of the University of Maryland (UMB Protocol
H23742).
Pancoast Tumor Identification
Patients demonstrating radiographic and clinical signs of superior
sulcus tumors were included. Preoperative pathologic diagnosis
was made with computed tomography (CT)–guided fine-needle
aspiration biopsy. Preresection lymph node stage was determined
by means of either transbronchial biopsy or mediastinoscopy in all
patients. Other radiologic examinations, such as brain CT or mag-
netic resonance imaging and positron emission tomography were
obtained as clinically warranted.
Induction Therapy Regimen
All patients underwent preoperative high-dose radiotherapy with
an intent-to-treat approach. Those patients receiving chemotherapy
in combination with radiotherapy began both treatments within 24
hours of each other. Weekly platinum-based combination chemo-
therapy was used in the majority of patients. Three-dimensional
conformal radiation therapy was administered as a large-field
45-Gy dose to the primary tumor and mediastinum, followed by a
small-field boost to the primary tumor beginning at 14.2 Gy.
Radiation portals were defined by means of 3-dimensional CT scan
reconstruction and tailored to minimize toxicity to nearby struc-
tures, such as the brachial plexus, esophagus, and spinal cord.
Surgical Approach
Three to 4 weeks after completion of the induction therapy, pa-
tients were reassessed. Patients who did not show evidence of local
disease progression or metastasis, as demonstrated on the basis of
surgical lymph node restaging, underwent thoracotomy for resec-
tion of the primary tumor. Operative approaches included standard
posterior-lateral, anterior-superior, and anterior hemiclamshell
thoracotomies. The choice of specific surgical approach was dic-
tated on the basis of the location and local invasiveness of the
primary tumor. At the time of the operation, a lobectomy or pneu-
monectomy was performed. Lesser pulmonary resections were not
used. Areas of direct tumor extension into the chest wall or spine were
resected en bloc with the involved lung. Neurosurgical-orthopedic
The Journal of Thoracicconsultation and operative assistance were used if spinal involvement
required more than simple resection of the transverse process or
wedge vertebral osteotomy. As needed, vertebrectomy was achieved
posteriorly first, followed by standard en bloc resection of the entire
specimen in continuity. Routine coverage of the bronchial stump with
an intercostal or serratus muscle flap was used. Harvesting of the
muscle flap was done on opening the chest. The choice of muscle flap
used was dependent on the patient’s anatomy and reach of the muscle
flap, as well as surgeon preference. In general, the serratus muscle was
used if the intercostal muscle bundle was insufficient or after pneu-
monectomy was performed. All visible and surgically accessible
bronchopulmonary, hilar, and mediastinal lymph nodes were removed
and submitted along with the primary lung resection specimen for
pathology review. A pathologic complete response (p-CR) was dem-
onstrated when the resected surgical specimen contained no evidence
of viable cancer. A resection was considered R0 when no viable
tumor was left in the operative field, whereas an R1 resection left only
microscopic tumor behind.
Patient Follow-up
After completion of multimodality treatment, all patients un-
derwent close follow-up at our institution. Patients were eval-
uated every 3 months during the first 2 years postoperatively
and then every 6 months thereafter on the basis of history,
physical examination, and chest CT scan. Brain magnetic res-
onance imaging and CT scanning were done annually for the
first 2 postoperative years or if symptoms indicated the need for
more frequent scanning.
Statistical Analyses
Survival was determined by using Kaplan-Meier analysis. Log
rank comparisons of survival were performed. Ninety-five percent
confidence intervals (CIs) were calculated where appropriate. All
patients are considered in the analysis of survival. Only patients
who underwent resection are considered in the analysis of patho-
logic response. All data were analyzed with Graph-Pad statistical
TABLE 1. Patient demographics (n  37)
No. of
patients
Percentage of all
patients
Sex
Male 22 60
Female 15 40
Preoperative stage NSCLC
IIB 18 49
IIIA 8 22
IIIB 6 16
IV (isolated brain metastasis) 5 13
Primary tumor histology
Squamous 12 32
Adenocarcinoma 12 32
Poorly differentiated 13 35
NSCLC, Non–small cell lung cancer.software (Graph Pad, Inc, San Diego, Calif).
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Patient Demographics
From 1993 through 2003, 37 patients presented to the Uni-
versity of Maryland Thoracic Oncology Program and re-
ceived multimodality treatment for superior sulcus lung
cancers. The study population (Table 1) included 22 men
(mean age, 55 years; range, 31-76 years) and 15 women
(mean age, 56 years; range, 36-74 years). Primary tumor
histology included squamous cell carcinoma (n  12), ad-
enocarcinoma (n  12), and poorly differentiated carci-
noma (n  13). After mediastinoscopic staging of the me-
diastinum, preoperative TNM classification of the cohort
revealed stage IIB (n  18), IIIA (n  8), IIIB (n  6), and
IV (n  5) disease (Table 2).
Thirty-six of 37 patients underwent neoadjuvant chemo-
radiation, followed by surgical resection. Early in the series,
one patient received preoperative high-dose radiation with-
out chemotherapy, followed by surgical resection. Thirty-
four of 37 patients received platinum-based combination
chemotherapy (carboplatin and paclitaxel, n  25; cisplatin
and etoposide, n  7; or cisplatin and vinorelbine [Navel-
TABLE 2. Distribution of patients with T3 and T4 superior
sulcus tumor
TNM classification No. of patients Percentage of all patients
Stage IIB
T3 N0 M0 18 49
Stage IIIA
T3 N2 M0 8 22
Stage IIIB 16
T3 N3 M0 1 2.7
T4 N0 M0 4 11
T4 N2 M0 1 2.7
Stage IV
T3 N0 M1 (brain)* 5 14
*All 5 patients presented with solitary brain metastasis and had negative
mediastinal lymph nodes demonstrated by means of preresectional
mediastinoscopy.Figure 1. Distribution of total radiation dosages.
1252 The Journal of Thoracic and Cardiovascular Surgery ● Junbine, GlaxoSmithKline], n  2). Two patients received
single-agent neoadjuvant carboplatin in conjunction with
high-dose radiotherapy. All but one patient completed the
target high-level radiation dose. (The one exceptional pa-
tient did not progress past 30 Gy because of severe esoph-
agitis, and this was experienced early in this series.) The
mean total radiation dose for the cohort overall is 56.9 Gy
(range, 30-70.2 Gy; Figure 1).
Surgical resection was feasible in all 37 patients and
included 34 lobectomies and 3 pneumonectomies (Table 3).
A small minority of tumors required pneumonectomy either
because of large bulky disease that contiguously crossed the
fissure (n  2) or because of central extension into the hilar
region (n 1). An R0 surgical resection was achieved in 36
(97.3%) patients; the remaining patient had residual micro-
scopic disease on the subclavian artery. This patient subse-
quently received subclavian stenting and additional focused
external beam irradiation to this area. One elderly patient
died in the perioperative period because of progressive
sepsis and adult respiratory distress syndrome at approxi-
mately 30 days after surgical intervention, yielding an op-
erative mortality rate of 2.7% (n  1/37). Significant mor-
bidities occurred in 10 patients (n  10/37, 27% patients)
but were variable and without a dominant pattern (Table 4).
Treatment Response and Survival Analysis
A p-CR was found in 40.5% (95% CI, 26%-59%; n  15)
of patients. Mean follow-up for our entire cohort was 24.7
TABLE 3. Data on surgical resection
No. of patients
Percentage of
all patients
Operation type
Exploratory thoracotomy 0 0
Lobectomy 34 92
Pneumonectomy 3 8
Completeness of resection
Surgically complete (R0, R1) 37 100
Pathologically complete (R0) 36 97
TABLE 4. Postoperative morbidity
Morbidity No. of patients
Percentage of all
patients
ARDS 2 5.4
Bronchopleural fistula 2 5.4
DVT 2 5.4
Prolonged atelectasis 2 5.4
Pulmonary embolus 1 2.7
Pneumonia 1 2.7
Hand paresthesia 1 2.7
Pleural effusion 1 2.7ARDS, Adult respiratory distress syndrome; DVT, deep venous thrombosis.
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cohort available to follow-up (n 36) is 31.6 months or 2.6
years (Figure 2). The MST for patients with p-CR was 93.1
months or 7.8 years (Figure 3). The MST for patients with
preresectional positive lymph nodes (n  12) remains un-
defined (MST not reached, Figure 4). The site of recurrence
did not appear to influence survival (Figure 5). Statistically
significant differences were not reached in survival compar-
isons involving p-CR, preresectional lymph node status, or
pattern of recurrence.
Recurrences and Disease Relapse
Recurrences were found in 50% (95% CI, 33%-67%; n 18)
of all treated patients. Distant recurrences occurred in a total of
13 patients, and the most common site of distant metastasis
was the brain (n  9, 50% total number recurrences, 25%
[95% CI, 12%-42%] of all patients). The remaining distant
Figure 2. Overall survival of all eligible patients with follow-up.Figure 3. Overall survival of p-CR versus no p-CR (P  .32).
The Journal of Thoracicrecurrences were accounted for by 4 patients (22.2% total
number recurrences, 11.1% [95% CI, 3%-26%] of all patients)
and included sites such as the adrenal, liver, and distant lymph
nodes. Local recurrences, notably in the lung-mediastinum,
occurred in 5 patients (27.7% total recurrences, 13.8% [95%
CI, 5%-30%] of all patients).
Discussion
Feasibility
One of the early challenges in treating Pancoast lung cancer
centered on resectability. The addition of preoperative ra-
diation, up to 30 to 35 Gy, as initiated by Shaw and Paulson,
did much to improve resectability rates but did not eliminate
unresectability. Before the advent of 3-dimensional confor-
mal radiotherapy, the total radiation dose that could be
safely delivered was constrained by dose-limiting toxicities
Figure 4. Survival by preresectional lymph node (LN) status (P .49).Figure 5. Recurrence pattern and survival (P  .71).
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to Pancoast tumors, as well as impaired tissue healing
postoperatively. Our present series demonstrates that high-
dose radiotherapy targeting to 60 Gy can be given in the
neoadjuvant setting and is successfully tolerated in more
than 97% of patients. Only 1 patient early in the series was
unable to tolerate radiation past 30 Gy because of intracta-
ble radiation-induced esophagitis. The relative lack of sig-
nificant radiation toxicity is directly attributable to the ben-
eficial merits of precise 3-dimensional conformal radiation
planning and the expertise of highly skilled radiation oncol-
ogy collaborators. The potential gains achieved in local
control from increased total radiation are tempered by the
potential complications resulting from bronchopulmonary
operations within an irradiated field. In our experience we
have attempted to mitigate these circumstances at the time
of the operation by avoiding unnecessary skeletonization
and devascularization of the remnant bronchial stump. In
addition, we have adopted the routine use of pedicled mus-
cle flaps to provide healthy vascularized unirradiated tissue
coverage to the bronchial stump.9 Although we experienced
2 postoperative bronchopleural fistulas in our series, the
incidence of this dreaded complication was remarkably
lower than would be otherwise anticipated given the high
doses of radiation used.
Surgical Outcomes
Resectability was possible in all our patients, and an R0
resection was achieved in 97% of patients. This compares
favorably with R0 resection rates seen in other contempo-
rary series: Southwest Oncology Group (SWOG)6
9416—45 Gy, T3 lesions (91%) and T4 lesions (87%); van
Geel and colleagues10—46 Gy plus intraoperative radiation
therapy (IORT) 10 Gy (48%).
Our survival analysis also compares favorably with those
from the SWOG 9416 trial. In SWOG 9416 T3 and T4
superior sulcus lungs with negative N2 lymph nodes were
treated with neoadjuvant chemoradiation consisting of com-
bination cisplatin and etoposide concurrent with 45 Gy of
radiation. The 2-year survival was 55% overall and 70% for
those patients in whom R0 or R1 resection was attained. In
our series we did not exclude patients with N2 involvement
and administered platinum-based combination chemother-
apy concurrent with average 56.9 Gy of radiation. We
observed a 2-year survival rate of 59%. The MST in our
overall cohort was 2.6 years, and the MST was 7.8 years for
patients with p-CRs. We also treated patients with Pancoast
tumors with stage 4 disease, those presenting with solitary
brain metastasis. Aggressive treatment of this notable subset
of patients with stage 4 Pancoast disease appears justified in
light of favorable survival data from patients with non-
Pancoast stage 4 disease with solitary brain metastasis in
other series.11,12
1254 The Journal of Thoracic and Cardiovascular Surgery ● JunMediastinal Lymph Nodes
We did not exclude patients with Pancoast tumors with
positive mediastinal lymph nodes from trimodality treat-
ment. Contemporary with our series, SWOG 9416 excluded
these patients from accrual, and we sought to offer treatment
comparable with those who were not eligible for SWOG
9416. Interestingly, in our survival analysis the MST for
patients with positive mediastinal lymph nodes was not
reached, and moreover, the survival curves between positive
and negative pretreatment mediastinal lymph nodes were
not statistically different. We speculate that perhaps the
inclusion of the mediastinum within the large-field irradia-
tion portal might sterilize any tumor cells within the medi-
astinal lymphatics and therefore negates any potential clin-
ical differences on the basis of nodal status. These results
might suggest that pretreatment positive mediastinal lymph
nodes should not necessarily preclude this subset of patients
with Pancoast lung cancer from benefiting from trimodality
treatment. However, there are few data to support proceed-
ing with surgical resection in the face of persistent lymph
node disease after completion of neoadjuvant therapy. The
favorable prognosis for patients who experience mediastinal
sterilization is consistent with the findings of other studies
of multimodality therapy in stage III disease.13,14
Role for Prophylactic Cranial Irradiation
The most common site of metastasis was the brain, which
accounted for 50% of all recurrences in our series and
affected 25% of patients. These data corroborate results
seen in other contemporary studies.6,15 Although Komaki
and associates15 did not see a statistical difference in the
frequency of brain metastasis between patients receiving
versus not receiving prophylactic cranial irradiation (PCI),
the group receiving PCI was disproportionately smaller in
number than the non-PCI group. This issue will likely
require a sufficiently powered study to determine the value
of PCI. One ongoing trial, Radiation Therapy Oncology
Group (RTOG) 0214, is a phase III study comparing PCI
versus observation in patients with stage IIIA and IIIB
non–small cell lung cancer. The target sample size is more
than 1000 patients, which will provide sufficient statistical
power to determine the efficacy of PCI. Because Pancoast
tumors are relatively rare, it is not feasible to perform a
similar PCI trial in only patients with Pancoast tumors.
Therefore the outcome of RTOG 0214 might hold great
interest for all who treat Pancoast tumors.
Study Limitations
The overall number of patients described in this series is
based on one institution’s experience. Despite inherent chal-
lenges with the coordination and execution of trimodality
therapy, our study is nonetheless limited by its relative small
size. This is especially unfortunate given the potentially
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node status: increased statistical power might have resulted
in statistically significant differences. Perhaps results such
as ours from the present series, along with other contempo-
rary experiences, might motivate consideration of a succes-
sor clinical trial to SWOG 9416, which might include pa-
tients with mediastinal lymph node involvement and
perhaps consider inclusion of PCI.
Summary
Surgical resection of Pancoast tumors after neoadjuvant
high-dose radiation therapy and chemotherapy can be safely
performed, with improved clinical outcomes. High-dose
radiation as part of a trimodality treatment regimen can be
successfully tolerated and might confer a survival advan-
tage. Pretreatment lymph node metastasis should not nec-
essarily exclude patients from trimodality treatment. Local
cancer control of Pancoast tumors can be accomplished with
aggressive trimodality therapy, but the high number of
distant metastases to the brain suggests that adjuvant PCI
might be necessary to optimize long-term results.
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Discussion
Dr Joseph Miller (Atlanta, Ga). The historical evolution of
successful treatment of Pancoast tumors dates from 1961, when the
report by Shaw and Paulson was first presented. It is now 43 years
later, and at the majority of the institutions, up until 2001, this
bimodality therapy remained the predominant mode of treatment.
In 2001, Valerie Rusch reported the results of the SWOG 9416
intergroup trial, which was the first time that combined chemo-
therapy and radiation therapy were done in a multi-institutional
setting. This opened the way for the trimodality therapy with
preoperative chemoradiation followed by surgical resection and
became pretty much the standard way that this was done. Now the
Maryland group has added high-dose 3-dimensional radiation with
doses varying in their reported series from 5000 to 7000 Gy, with
the majority being at around 5700 to 5800 Gy. The SWOG trial
stopped at 4500 Gy.
With this historical background, I have a few remarks and
questions for the author. In their group they took on all comers.
They had 18 patients with stage IIB, 8 patients with stage IIIA,
6 patients with stage IIIB, and 5 patients with stage IV disease.
It is of note that in the article mediastinoscopy was performed
in all patients before lymph node staging and before treatment.
Complete resection was accomplished in an amazing number,
97.3%, with a confirmed pathologic response, with 15 patients
being 41.7%. It is noted that they had a very high recurrence
rate, higher than is reported in the majority of series, with a
recurrence rate of 18 patients, with a rate of 50%, the highest
being noted by most centers always as being in the brain.
Median survival for the entire group was 2.6 years, but for the
complete pathologic response, it was 7.8 years. Perhaps one of
the most interesting and yet to be determined points in the
article is the following remark: “The median survival time of
patients with positive preoperative lymph nodes remains unde-
termined because the number is not reached.”
The authors state that pretreatment lymph node metastasis
should not exclude patients from this modality. They also point out
that with the high incidence of brain metastases, perhaps prophy-
lactic cranial irradiation should be added to the standard armamen-
tarium. The authors note that 3-dimensional radiation was given
with 4500 Gy but with the additional boost of 14.2 Gy to the target
area.
I would now like to ask the authors 3 questions. First, the
authors reported using 3 different surgical approaches. Which one
do they favor, and when is each indicated?Dr Kwong. Thank you, Dr Miller, for your kind comments.
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the posterior approach a la Paulson and Shaw. This approach is
most common when we have the posterior associated Pancoast
tumors without vessel or obvious brachial plexus involvement. Our
second most common approach is the anterior Dartevelle ap-
proach, and that can be performed in a single stage or in 2 stages.
For those apical tumors that are most anterior without posterior
involvement, this can be performed in a single stage. For those that
involve the posterior aspect of the chest wall, we do it in 2 stages,
and that involves an anterior approach with a posterior approach.
We find that the posterior approach adds a lot to the facility in
terms of dissection in the hilum and the lymph nodes, at least in
our experience. Lastly, the anterior clamshell approach, in which
we perform a sternotomy and then tee it off in the neck along the
border of the sternocleidomastoid, is very useful for those tumors
that are abutting or potentially involve the great vessels, such as
the innominate artery or the superior vena cava.
Dr Miller. My second question has 2 parts. The recurrence rate
of 50% is higher than is reported in most series. How do the
authors account for this? Is it because you are operating on all
comers, including those with stage III and IV disease, and do you
believe that this is justified?
Dr Kwong. Well, that is a very intriguing question. The
recurrence of 50% is a little higher than that seen in other series,
but we included patients who had a higher stage because of the
mediastinal lymph node involvement, and that could perhaps
play into the higher recurrence rate. The most common site of
recurrence was the brain, and that is consistent with other
series. As far as whether to include these patients, I think the
telltale sign, although not definitive, is the breakdown slide of
our median survival between those with positive and negative
lymph nodes. I think the safe and only thing we can take away
from that limited breakdown is that at least the group with
positive lymph nodes did no worse than the group with negative
lymph nodes, and therefore that seems to perhaps provide some
degree of justification for inclusion.
Dr Miller. Finally, in the fact that essentially no patient was
denied trimodality treatment, why not perform mediastinoscopy
after the induction therapy with the chemotherapy and radiation
and, if the nodes are positive, abort the procedure? I think this
might decrease your high recurrence rate. I would appreciate your
commenting on that, and I thank the association for the privilege
of discussing this article.
Dr Kwong. Thank you, Dr Miller, for all of your questions.
The answer to that last question is, interestingly enough, that in
all of our resection specimens, perhaps because of dumb luck,
there was no lymph node involvement after treatment. Therefore
that might not have impacted as well. However, your point is very
important, and we now routinely do restaging mediastinoscopy,
even after this type of induction treatment. If we were to encounter
a patient who has mediastinal lymph node involvement at this
stage, that patient would not be offered a surgical resection on the
basis of the data we have across the literature today.
Dr Robert J. Cerfolio (Birmingham, Ala). Excellent work. I
have a question and a comment, and it is very similar to Dr
Miller’s last question concerning when to do a mediastinoscopy. In
my practice this is an example of a select group of patients that I
do not do mediastinoscopy on if I suspect N2 disease: I will do it
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believe that repeat mediastinoscopy is safe and accurate after
high-dose radiation, and I do not believe it is either, then why not
save the mediastinoscopy for after the induction chemoradiother-
apy. In general, because we all make some exceptions for the
young healthy patients with recalcitrant N2 disease, do you offer
resection for patients with recalcitrant N2 or N3 disease or do you
deny resection and offer more chemotherapy, radiotherapy, or
both?
Dr Kwong. Thank you very much, Dr Cerfolio.
I think I touched a little bit on that in the last question from Dr
Miller. If the patient still presents with a recalcitrant lymph node
that is not in direct juxtaposition to the primary tumor, those are
patients who we would not go ahead and resect. However, if the
lymph node is very close by, I think we sometimes reserve judg-
ment to be very aggressive with these rare patients, and our current
results might seem to provide a small justification for that.
Dr Cerfolio. Therefore, in selected patients with N2 disease,
you would offer resection. A final important comment is that we
are finding a survival advantage in our own data in patients who
receive 60 Gy versus 45 Gy or less of preoperative radiation (not
patients with Pancoast tumors but those with N2 disease), and I
think we need to consider a prospective randomized trial looking
at this question in an ACOSOG of some other type of multi-
institutional trial setting.
Dr Kwong. Thank you, Dr Cerfolio. I think that is a great last
point. We can only speculate that perhaps our higher dose of
radiation, especially when we have mediastinal involvement, that
the large-field dose should encompass the mediastinum. In the
SWOG study, N2 lymph nodes were excluded, and therefore there
was no mediastinal sterilization with radiation. Perhaps mediasti-
nal sterilization with our high-dose radiation might confer a sur-
vival advantage to that group equal to those who have negative
lymph nodes at the time of preresection or pretreatment.
Dr Scott J. Swanson (New York, NY). Interesting and impres-
sive series. I have one quick question. You only had one patient
with subclavian vein involvement. Did you need to take vertebral
body or the brachial plexus or any other structures in any of those
cases given all the IIIB disease, and if you encounter positive
margins, what is your intraoperative approach?
Dr Kwong. The answer is yes in terms of finding patients who
have a small degree of involvement of the brachial plexus. If it is
on the lower edge, we might go ahead and be a little bit aggressive.
In terms of posterior vertebral involvement, we do see that, and
actually a couple of our patients are included in that series. If it is
just the transverse process or a partial osteotomy, we are very
comfortable in performing that part of the procedure ourselves.
However, if it is much more involved, where you have to take
more of a hemivertebrectomy, then we involve neurosurgery or
orthopedic consultation ahead of time and have them assist us in
the operating room. In those cases they will go ahead and do the
posterior aspect first and then we will go back and do the anterior
aspect subsequently.
Dr Krasna. I thank everybody for their comments.
Dr Cerfolio hit on a couple of very good points. There is
currently a new RTOG trimodality protocol. That protocol will
have mediastinoscopy up front and then restaging, but actually,
we excluded Pancoast tumors. Right now in our institution, in
e 2005
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Dr Miller and Dr Cerfolio, and that is that we are waiting on the
mediastinoscopy until after chemoradiation because of these
results.
Lastly, Joe, just to comment, the other thing that you alluded to
and that I do not want anybody to forget is that the morbidity ofThe Journal of Thoracichigh in terms of the local symptoms. I credit Joe McLaughlin for
really pushing me in this area because one of the worst things is
having a patient with a T4 Pancoast tumor who has received
chemoradiation or radiation and you do not resect. Many of those
patients go on with a horrible painful existence. Therefore we have
become very aggressive also in terms of the local control to allowG
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